Log in
NASDAQ:RIGL

Rigel Pharmaceuticals Stock Forecast, Price & News

$3.01
-0.05 (-1.63 %)
(As of 12/3/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.97
Now: $3.01
$3.07
50-Day Range
$2.44
MA: $2.69
$3.11
52-Week Range
$1.23
Now: $3.01
$5.24
Volume2.01 million shs
Average Volume3.59 million shs
Market Capitalization$508.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trials for warm autoimmune hemolytic anemia; R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trials for autoimmune and inflammatory diseases; and R552, a receptor-interacting protein kinase Inhibitor that is in phase I clinical trials for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Rigel Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RIGL
CUSIP76655960
Phone650-624-1100
Employees163

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.29 million
Book Value$0.32 per share

Profitability

Net Income$-66,890,000.00

Miscellaneous

Market Cap$508.63 million
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$3.01
-0.05 (-1.63 %)
(As of 12/3/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

How has Rigel Pharmaceuticals' stock been impacted by COVID-19?

Rigel Pharmaceuticals' stock was trading at $1.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RIGL stock has increased by 66.3% and is now trading at $3.01.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Rigel Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Rigel Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Rigel Pharmaceuticals?

Wall Street analysts have given Rigel Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rigel Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Rigel Pharmaceuticals
.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.04. The biotechnology company earned $18.39 million during the quarter, compared to the consensus estimate of $17.60 million. Rigel Pharmaceuticals had a negative return on equity of 37.85% and a negative net margin of 23.16%.
View Rigel Pharmaceuticals' earnings history
.

What price target have analysts set for RIGL?

5 brokers have issued 12-month price targets for Rigel Pharmaceuticals' shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate Rigel Pharmaceuticals' share price to reach $7.50 in the next twelve months. This suggests a possible upside of 149.2% from the stock's current price.
View analysts' price targets for Rigel Pharmaceuticals
.

Are investors shorting Rigel Pharmaceuticals?

Rigel Pharmaceuticals saw a increase in short interest in October. As of October 30th, there was short interest totaling 24,420,000 shares, an increase of 18.0% from the October 15th total of 20,700,000 shares. Based on an average daily trading volume, of 2,670,000 shares, the short-interest ratio is currently 9.1 days.
View Rigel Pharmaceuticals' Short Interest
.

Who are some of Rigel Pharmaceuticals' key competitors?

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the following people:
  • Mr. Raul R. Rodriguez, Pres & CEO (Age 59, Pay $1.01M)
  • Mr. Dean L. Schorno CPA, Exec. VP & CFO (Age 57, Pay $612.53k)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 55, Pay $761.28k)
  • Dr. Esteban S. Masuda, Exec. VP of Research (Age 58, Pay $537.21k)
  • Dr. Wolfgang Dummer M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 54, Pay $170.22k)
  • Mr. Joseph Lasaga, Sr. VP of Corp. Devel. (Age 45)
  • Ms. Lily Cheung, VP of HR
  • Mr. David A. Santos, Exec. VP & Chief Commercial Officer
  • Mr. Tarek Sallam, VP of Marketing

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.18%), State Street Corp (5.98%), Morgan Stanley (1.71%), Arrowstreet Capital Limited Partnership (0.99%), Sector Gamma AS (0.81%) and Acadian Asset Management LLC (0.71%).
View institutional ownership trends for Rigel Pharmaceuticals
.

Which institutional investors are selling Rigel Pharmaceuticals stock?

RIGL stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Wells Fargo & Company MN, JPMorgan Chase & Co., Acadian Asset Management LLC, J. Goldman & Co LP, Squarepoint Ops LLC, Jane Street Group LLC, and BlackRock Inc..
View insider buying and selling activity for Rigel Pharmaceuticals
.

Which institutional investors are buying Rigel Pharmaceuticals stock?

RIGL stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Morgan Stanley, Sector Gamma AS, Arrowstreet Capital Limited Partnership, Assenagon Asset Management S.A., SG Americas Securities LLC, Cubist Systematic Strategies LLC, and Dupont Capital Management Corp.
View insider buying and selling activity for Rigel Pharmaceuticals
.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $3.01.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $508.63 million and generates $59.29 million in revenue each year. The biotechnology company earns $-66,890,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Rigel Pharmaceuticals employs 163 workers across the globe.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is www.rigel.com.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.